Nordic Bioscience AS
www.nordicbioscience.com
Latest From Nordic Bioscience AS
Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements
Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working to validate non-invasive biomarkers for diagnosis, prognosis and treatment impact.
Deals Shaping The Medical Industry, July 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
Lilly Pays KeyBioscience $55m Up Front to Expand Its Early Diabetes Pipeline
Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.
Stealthy NGM And Bristol Emerge As Serious NASH Competitors
No longer quiet NGM Bio unveils Phase II data at EASL showing rapid and significant reductions of hepatic fat, while Bristol announces a partnership to produce a non-invasive diagnostic for NASH and presents promising Phase II data for its FGF21 analogue.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Alias(es)
- Ownership
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Scandinavia
-
Denmark
-
Denmark
-
Scandinavia
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Nordic Bioscience AS
- Senior Management
-
Morten A Karsdal, CEO
Thomas Nielsen, CFO - Contact Info
-
Nordic Bioscience AS
Phone: 4452 5252
Herlev Hovedgade 207
Herlev, DK-2730
Denmark
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice